A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Phase 4

Completed

• Conditions: Hypertension
• Interventions: Drug: Cantabell Tab; Drug: Candemore Plus Tab

• Registration Number: NCT04521023
• Lead Sponsor: Chong Kun Dang Pharmaceutical

Brief Summary

Phase 4 clinical trial to Evaluate the blood pressure lowering effect of a Candesartan/Hydrochlorothiazide(Candemore Plus Tab) versus Candesartan/Amlodipine(Cantabell Tab) in Hypertensive Patients

Detailed Description

Not available

Study Timeline

• Study Start: 2017-09-20
• Primary Completion: 2020-01-28
• Study Completion: 2020-06-03
• Status Verified: 2020-08
• Study First Submitted: 2020-08-18
• Study First Submitted QC: 2020-08-18
• Last Update Submitted: 2020-08-18
• Study First Posted: 2020-08-20
• Last Update Posted: 2020-08-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 132

Inclusion Criteria

• over 19 years old
• Agreement with written informed consent
• Hypertensive Patients

Read More

Exclusion Criteria

• Patients with secondary hypertension
• Participated in other trial within 30 days
• In investigator's judgement

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
A	Cantabell Tab	-
B	Candemore Plus Tab	-

Primary Outcome Measures

Name	Time	Method
cSBP(central Systolic Blood Pressure)	change after 8 weeks compared to baseline	Average cSBP change after 8 weeks compared to baseline

Secondary Outcome Measures

Name	Time	Method
cDBP(central Diastolic Blood Pressure)	change after 8 weeks compared to baseline	Average cDBP change after 8 weeks compared to baseline
sitSBP(sitting Systolic Blood Pressure)	change after 8 weeks compared to baseline	Average sitSBP change after 8 weeks compared to baseline
sitDBP(sitting Diastolic Blood Pressure)	change after 8 weeks compared to baseline	Average sitDBP change after 8 weeks compared to baseline

Trial Locations

Locations (14)

Ajou University Hospital; 🇰🇷 Suwon, Gyeonggi-do, Korea, Republic of

Jeju National University Hospital; 🇰🇷 Jeju, Korea, Republic of

Daegu Catholic Univ. Medical Center; 🇰🇷 Daegu, Korea, Republic of

Hallym Univ. Medical Center; 🇰🇷 Anyang, Korea, Republic of

Gangnam Severance Hospital; 🇰🇷 Seoul, Korea, Republic of

Wonju Severance Christian Hospital; 🇰🇷 Wŏnju, Korea, Republic of

Inje University Ilsan Paik Hospital; 🇰🇷 Ilsan-gu, Korea, Republic of

Gachon University Gil Medical Center; 🇰🇷 Incheon, Korea, Republic of

MYONGJI Hospital; 🇰🇷 Goyang-si, Korea, Republic of

Hanyang University Medical Center; 🇰🇷 Seoul, Korea, Republic of

Hallym University Kangnam Sacred Heart Hospital; 🇰🇷 Seoul, Korea, Republic of

Kangbuk Samsung Hospital; 🇰🇷 Seoul, Korea, Republic of

SNU Boramae Medical Center; 🇰🇷 Seoul, Korea, Republic of

Ulsan University Hospital; 🇰🇷 Ulsan, Korea, Republic of